Marburg virus reaches Rwanda: how close are we to a vaccine solution?
Marburg virus disease (MVD) is a highly virulent and often fatal disease caused by the Marburg virus, a member of the Filoviridae family, closely related to the Ebola virus. Historically, outbreaks have been sporadic but lethal across various African countries, with high case fatality rates (CFRs)....
Saved in:
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-04-01
|
Series: | International Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971224004466 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1841545999874523136 |
---|---|
author | Olivier Sibomana Clyde Moono Hakayuwa Jildas Munyantore |
author_facet | Olivier Sibomana Clyde Moono Hakayuwa Jildas Munyantore |
author_sort | Olivier Sibomana |
collection | DOAJ |
description | Marburg virus disease (MVD) is a highly virulent and often fatal disease caused by the Marburg virus, a member of the Filoviridae family, closely related to the Ebola virus. Historically, outbreaks have been sporadic but lethal across various African countries, with high case fatality rates (CFRs). In 2023, significant outbreaks occurred in Tanzania and Equatorial Guinea, with CFRs of 62.5% and 75%, respectively. In 2024, Rwanda faced its first outbreak, starting on September 27, 2024. By November 8, 2024, Rwanda had conducted 7,408 tests, confirming 66 cases, 15 of which were fatal, and 51 recoveries. Although no approved vaccine currently exists for MVD, global health authorities are prioritizing the development of effective vaccines. Drawing on insights from the rapid COVID-19 vaccine development, several promising candidates are under exploration, with the cAd3-MARV showing notable potential. This paper examines the current MVD outbreak in Rwanda and the progress toward developing a long-term vaccine solution. |
format | Article |
id | doaj-art-a2a94011df2348058c17cf4ac6629189 |
institution | Kabale University |
issn | 1201-9712 |
language | English |
publishDate | 2025-04-01 |
publisher | Elsevier |
record_format | Article |
series | International Journal of Infectious Diseases |
spelling | doaj-art-a2a94011df2348058c17cf4ac66291892025-01-11T06:38:38ZengElsevierInternational Journal of Infectious Diseases1201-97122025-04-01153107371Marburg virus reaches Rwanda: how close are we to a vaccine solution?Olivier Sibomana0Clyde Moono Hakayuwa1Jildas Munyantore2Department of General Medicine and Surgery, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda; Corresponding author: Olivier Sibomana, Department of General Medicine and Surgery, College of Medicine and Health Sciences, University of Rwanda, KG 11 Ave, Kigali, Rwanda.Department of Public Health, Copperbelt University, Ndola, ZambiaDepartment of General Medicine and Surgery, College of Medicine and Health Sciences, University of Rwanda, Kigali, RwandaMarburg virus disease (MVD) is a highly virulent and often fatal disease caused by the Marburg virus, a member of the Filoviridae family, closely related to the Ebola virus. Historically, outbreaks have been sporadic but lethal across various African countries, with high case fatality rates (CFRs). In 2023, significant outbreaks occurred in Tanzania and Equatorial Guinea, with CFRs of 62.5% and 75%, respectively. In 2024, Rwanda faced its first outbreak, starting on September 27, 2024. By November 8, 2024, Rwanda had conducted 7,408 tests, confirming 66 cases, 15 of which were fatal, and 51 recoveries. Although no approved vaccine currently exists for MVD, global health authorities are prioritizing the development of effective vaccines. Drawing on insights from the rapid COVID-19 vaccine development, several promising candidates are under exploration, with the cAd3-MARV showing notable potential. This paper examines the current MVD outbreak in Rwanda and the progress toward developing a long-term vaccine solution.http://www.sciencedirect.com/science/article/pii/S1201971224004466MarburgOutbreaksVaccinesRwanda |
spellingShingle | Olivier Sibomana Clyde Moono Hakayuwa Jildas Munyantore Marburg virus reaches Rwanda: how close are we to a vaccine solution? International Journal of Infectious Diseases Marburg Outbreaks Vaccines Rwanda |
title | Marburg virus reaches Rwanda: how close are we to a vaccine solution? |
title_full | Marburg virus reaches Rwanda: how close are we to a vaccine solution? |
title_fullStr | Marburg virus reaches Rwanda: how close are we to a vaccine solution? |
title_full_unstemmed | Marburg virus reaches Rwanda: how close are we to a vaccine solution? |
title_short | Marburg virus reaches Rwanda: how close are we to a vaccine solution? |
title_sort | marburg virus reaches rwanda how close are we to a vaccine solution |
topic | Marburg Outbreaks Vaccines Rwanda |
url | http://www.sciencedirect.com/science/article/pii/S1201971224004466 |
work_keys_str_mv | AT oliviersibomana marburgvirusreachesrwandahowclosearewetoavaccinesolution AT clydemoonohakayuwa marburgvirusreachesrwandahowclosearewetoavaccinesolution AT jildasmunyantore marburgvirusreachesrwandahowclosearewetoavaccinesolution |